ClinicalTrials.gg
CompletedNCT03202979Updated Sep 28, 2018

Trazodone in Painful Diabetic Neuropathy

A Phase 2 interventional study of Trazodone 20 mg and Trazodone 10 mg in Painful Diabetic Neuropathy, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 20 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-09-28.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Diabetic Neuropathies with a site in Czechia — 1 open to participants now, 1 under way, none of them phase 3. Diabetic Neuropathies · Czechia.

Enrollment
8th of 11
142 · median 193
Started
2017
the only one that year
Phase 2
9 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
2 of 11
Aziende Chimiche Riunite Angelini Francesco S.p.A

Among the 11 studies in Diabetic Neuropathies with a site in Czechia, this one is the 8th largest by enrollment, is the only one that started in 2017, is one of 9 in phase 2, and was the 7th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

1 of the 11 studies in Diabetic Neuropathies with a site in Czechia is open now. Recruiting first, the newest first:

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetic Neuropathies with a site in Czechia, or all of them as a file.
02

Study summary

The aim of the study is to collect preliminary information on the effect of low doses of trazodone on pain intensity in patients with painful diabetic neuropathy and to evaluate the neuropathic pain symptoms, anxiety, sleep, quality of life, safety and tolerability.

Read the detailed description

This is a randomized, double-blind, placebo controlled, double-dummy, dose finding, parallel group, multicentre, international, prospective, pilot study.

The present study is planned to assess the efficacy and the safety of an 8-week treatment period with low doses of trazodone (30 mg daily or 60 mg total daily, respectively) administered to patients affected by painful diabetic neuropathy.

Gabapentin will be administered together with the investigational drug in open label conditions in order to assure an effective pharmacological treatment to all patients. A slow titration of gabapentin will be applied in this trial in order to control possible side effects when co-administered with trazodone.

03

Conditions studied

  • Painful Diabetic Neuropathy

Keywords

  • Trazodone
  • Placebo
  • Gabapentin
  • Neuropathic pain
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patient of any ethnic origin between 18 and 75 years of age (limits included).
  2. Patient with painful diabetic symmetric polyneuropathy manifesting with distally distributed neuropathic pain.
  3. Stable glycaemic control with a value of ≤ 10% at Screening Visit.
  4. Pain persisting for at least 3 months.
  5. Neuropathic pain confirmed by DN4 score ≥ 4 at Screening Visit.
  6. BPI-SF 24-hour average pain score (item 5) ≥ 4 at Screening Visit and Baseline Visit.
  7. Patient who is currently not receiving treatment for diabetic neuropathic pain or patient who is receiving treatment, with drug/s other than gabapentin, and have completed the required .
  8. Women of must have a negative pregnancy test at Screening Visit and have to agree not to start a pregnancy from the signature of the up to thirty days after the last administration of the product, using an appropriate method, such as combined estrogen and progestogen containing hormonal contraception (e.g. oral, intravaginal, transdermal), progestogen-only hormonal contraception (e.g. oral, injectable, implantable), intrauterine device (IUD) or intrauterine hormone- releasing system (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence.
  9. Legally capable to give their consent to participate in the study and available to sign and date the written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Known to trazodone or gabapentin or their .
  2. Other forms of neuropathic pain or non-neuropathic pain (included but not limited to peripheral arterial disease, radiculopathy, mononeuropathy, proximal motor neuropathy, post-operative pain, etc).
  3. Concomitant treatment with other medications for pain management.
  4. Concomitant treatment with potent inhibitors (e.g. ketoconazole, ritonavir, indinavir) or drugs known to prolong .
  5. Use of trazodone or gabapentin in the previous 3 months.
  6. abnormalities on physical examination, vital signs, , laboratory tests at Screening Visit that in the opinion of Investigator would compromise patient's participation in the study.
  7. Active foot ulcer or previous major limb amputation.
  8. Myocardial infarction or angioplasty or by-pass graft procedures within the past 6 months.
  9. Patient with increased risk of Torsade de Pointes (e.g. family history of long QT syndrome) or QTcF value higher than 450 msec (male) and QTcF value higher than 470 msec (female) at Screening Visit.
  10. or cerebral vascular accident within the past 6 months.
  11. value \< 60 ml/min calculated with MDRD formula.
  12. Significant liver disease, defined as known active hepatitis or elevated liver enzymes over 3 fold the upper normal limit of laboratory normal ranges.
  13. Patient with latent or known hereditary problems of galactose intolerance or the Lapp lactase deficiency or glucose-galactose malabsorption.
  14. Positive urine drug screen for CNS active drugs (cocaine, opioids, amphetamines and cannabinoids) a Screening Visit.
  15. Positive present history of glaucoma.
  16. Hyperthyroidism, even if pharmacologically corrected.
  17. Significant mental disorders.
  18. History of seizure events other than a single childhood febrile seizure.
  19. History of alcohol or psychoactive substance abuse or addiction.
  20. Patient suffering from adrenal hypofunction (e.g. Addison's disease).
  21. Women during pregnancy or lactation period.
  22. Inability to comply with the protocol requirements, instructions or study-related restrictions (e.g. uncooperative attitude, inability to return for study-visits, improbability of completing the clinical study, etc).
  23. Subject involved in the conduct of the study (e.g. Investigator or his/her deputy, first grade relatives, pharmacist, assistant or other personnel, etc).
  24. Participation to an interventional clinical trial within 3 months prior to Screening Visit.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Group 1

    Trazodone 20 mg

    Drug: Trazodone 20 mg

  • Experimental
    Group 2

    Trazodone 10 mg

    Drug: Trazodone 10 mg

  • Placebo comparator
    Group 3

    Placebo

    Drug: Placebo

Interventions

  • Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg. After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions.

    Also known as: Trittico®

  • Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg. In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops). After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.

    Also known as: Trittico®

  • DrugPlacebo

    Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment. After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.

06

What researchers measure

Primary outcomes

  1. Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 5 score in BPI-SF numering scale after 56 days.

    Time frame: Baseline - Day 56

Secondary outcomes

  1. Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 5 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 63

  2. Change of item 3 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 3 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  3. Change of item 4 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 4 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  4. Change of item 5 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 5 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  5. Change of item 6 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 6 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  6. Change of item 8 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 8 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  7. Change of item 9 score in Brief Pain Inventory Short Form (BPI-SF) scale

    Change from baseline of item 9 score in BPI-SF numering scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  8. Change in Neuropathic Pain Symptom Inventory (NPSI) scale

    Change from baseline of total score in NPSI scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  9. Change in 36-item Short-Form Health Survey (SF-36)

    Change from baseline of SF-36 after 56 days.

    Time frame: Baseline - Day 56

  10. Change in Hamilton Anxiety Rating Scale (HAM-A)

    Change from baseline of total score in HAM-A scale after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  11. Patient Global Impression of Change (PGIC)

    Assessment by patient of the overall efficacy and tolerability by PGIC after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days

    Time frame: Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  12. Change in Leeds Sleep Evaluation Questionnaire (LSEQ)

    Change from baseline in LSEQ after 7, 14, 21, 28, 35, 42, 49, 56 and 63 days.

    Time frame: Baseline - Days 7, 14, 21, 28, 35, 42, 49, 56 and 63.

  13. Frequency of treatment-related adverse events

    Monitoring of the frequency of adverse events, physical examination, vital signs, ECG, laboratory analyses

    Time frame: 9 weeks

07

Study locations

20 sites
  • NEUROHK s.r.o.
    Chocen, 565 01, Czechia
  • Litnea s.r.o. Neurologicka ambulance
    Litomerice, 412 01, Czechia
  • Neurosanatio s.r.o.
    Litomysl, 570 01, Czechia
  • MP-neuro s.r.o. Poliklinika Modry pavilon
    Ostrava, 710 00, Czechia
  • Nemocnice Pardubickeho kraje a.s. Pardubicka nemocnice Neurologická klinika
    Pardubice, 532 03, Czechia
  • Diabetologicka ambulance Milan Kvapil s.r.o.
    Praha 4, 149 00, Czechia
  • Vestra Clinics s.r.o.
    Rychnov nad Knežnou, 516 01, Czechia
  • Budai Irgalmasrendi Korhaz Belgyógyászati Centrum
    Budapest, 1027, Hungary
  • Semmelweis Egyetem AOK I. sz. Belgyogyaszati Klinika
    Budapest, 1083, Hungary
  • Markhot Ferenc Oktatokorhaz es Rendelointezet Diabetesz Gondozo
    Eger, 3300, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz I. sz. Belgyogyaszati Osztaly
    Gyula, 5700, Hungary
  • Bacs-Kiskun Megyei Korhaz II. sz. Belgyogyaszati Osztaly
    Kecskemet, 6000, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont I. Sz. Belgyogyaszati Klinika
    Szeged, 6720, Hungary
  • Silmedic Sp. z o.o.
    Katowice, 40-282, Poland
  • Pro Familia Altera Sp. z o.o.
    Katowice, 40-648, Poland
  • NZOZ Neuromed M. i M. Nastaj Sp. P.
    Lublin, 20-064, Poland
  • RCMed Oddział Sochaczew
    Sochaczew, 96-500, Poland
  • Jeka Sławomir Niepubliczny Zakład Opieki Zdrowotnej "Nasz Lekarz" Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna
    Torun, 87-100, Poland
  • NBR Polska Tomasz Klodawski
    Warszawa, 00-465, Poland
  • Medycyna Kliniczna
    Warszawa, 00-660, Poland
08

References and documents

Publications

  • Lipone P, Ehler E, Nastaj M, Palka-Kisielowska I, Cruccu G, Truini A, Di Loreto G, Del Vecchio A, Pochiero I, Comandini A, Calisti F, Cattaneo A. Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy and Treated with Gabapentin: A Randomized Controlled Pilot Study. CNS Drugs. 2020 Nov;34(11):1177-1189. doi: 10.1007/s40263-020-00760-2. PubMed 32936427 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Aug 2018, 14 months.

Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2017
First posted
Jun 29, 2017
StartActual
May 16, 2017
Primary completionActual
Aug 9, 2018
CompletionActual
Aug 9, 2018
Last update
Sep 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03202979
Collaborators
Chiltern International Inc.
Responsible party
Sponsor
First posted
Jun 29, 2017
Start date
May 16, 2017
Primary completion
Aug 9, 2018
Completion
Aug 9, 2018
Last update
Sep 28, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion